{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,9,21]],"date-time":"2025-09-21T18:30:31Z","timestamp":1758479431464,"version":"3.44.0"},"reference-count":26,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2025,5,5]],"date-time":"2025-05-05T00:00:00Z","timestamp":1746403200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,5,5]],"date-time":"2025-05-05T00:00:00Z","timestamp":1746403200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Int J Hematol"],"published-print":{"date-parts":[[2025,9]]},"DOI":"10.1007\/s12185-025-03996-0","type":"journal-article","created":{"date-parts":[[2025,5,5]],"date-time":"2025-05-05T05:12:53Z","timestamp":1746421973000},"page":"449-453","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["COVID-19-induced thrombotic microangiopathy in patients with multiple myeloma receiving carfilzomib treatment"],"prefix":"10.1007","volume":"122","author":[{"ORCID":"https:\/\/orcid.org\/0009-0000-4957-9058","authenticated-orcid":false,"given":"Kaito","family":"Takikawa","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mana","family":"Sota","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shiori","family":"Nakashima","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yui","family":"Imai","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hirofumi","family":"Nakano","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tomoyuki","family":"Uchida","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Morihiro","family":"Inoue","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Masao","family":"Hagihara","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Akiko","family":"Torii","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,5,5]]},"reference":[{"key":"3996_CR1","doi-asserted-by":"publisher","first-page":"1681","DOI":"10.2169\/internalmedicine.9209-21","volume":"61","author":"T Fujii","year":"2022","unstructured":"Fujii T, Hagihara M, Mitamura K, Nakashima S, Ohara S, Uchida T, et al. Anti-SARS CoV-2 IgG in COVID-19 patients with hematological diseases: a single-center, retrospective study in Japan. Intern Med. 2022;61:1681\u20136.","journal-title":"Intern Med"},{"key":"3996_CR2","doi-asserted-by":"publisher","first-page":"191","DOI":"10.1016\/j.thromres.2021.04.012","volume":"202","author":"NR Tiwari","year":"2021","unstructured":"Tiwari NR, Phatak S, Sharma VR, Agarwal SK. COVID-19 and thrombotic microangiopathies. Thromb Res. 2021;202:191\u20138.","journal-title":"Thromb Res"},{"key":"3996_CR3","doi-asserted-by":"publisher","first-page":"465","DOI":"10.1016\/j.amjms.2021.10.012","volume":"363","author":"J Plasek","year":"2022","unstructured":"Plasek J, Gumulec J, Maca J, Skarda J, Prochazka V, Grezl T, et al. COVID-19 associated coagulopathy: mechanisms and host-directed treatment. Am J Med Sci. 2022;363:465\u201375.","journal-title":"Am J Med Sci"},{"key":"3996_CR4","doi-asserted-by":"publisher","first-page":"309","DOI":"10.1007\/s11739-020-02601-y","volume":"16","author":"M Levi","year":"2021","unstructured":"Levi M, Iba T. COVID-19 coagulopathy: is it disseminated intravascular coagulation? Intern Emerg Med. 2021;16:309\u201312.","journal-title":"Intern Emerg Med"},{"key":"3996_CR5","doi-asserted-by":"publisher","first-page":"657","DOI":"10.1007\/s11239-020-02297-z","volume":"51","author":"X Wang","year":"2020","unstructured":"Wang X, Sahu KK, Cerny J. Coagulopathy, endothelial dysfunction, thrombotic microangiopathy and complement activation: potential role of complement system inhibition in COVID-19. J Thromb Thrombolysis. 2020;51:657\u201362.","journal-title":"J Thromb Thrombolysis"},{"key":"3996_CR6","doi-asserted-by":"publisher","first-page":"1102","DOI":"10.1080\/10428194.2022.2057485","volume":"63","author":"T Terao","year":"2022","unstructured":"Terao T, Tsushima T, Miura D, Ikeda D, Fukumoto A, Kuzume A, et al. Carfilzomib-induced thrombotic microangiopathy is underestimated in clinical practice: a report of five patients and literature review. Leuk Lymphoma. 2022;63:1102\u201310.","journal-title":"Leuk Lymphoma"},{"key":"3996_CR7","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1038\/s41408-023-00885-9","volume":"13","author":"R Ponraj","year":"2023","unstructured":"Ponraj R, Bryant A, Dunlop L, Range H, Cobrador C, Ling S, et al. Carfilzomib-induced thrombotic microangiopathy (TMA): an under-recognised spectrum of disease from microangiopathic haemolysis to subclinical TMA. Blood Cancer J. 2023;13:113.","journal-title":"Blood Cancer J"},{"key":"3996_CR8","doi-asserted-by":"publisher","first-page":"750","DOI":"10.1111\/bjh.17377","volume":"193","author":"M Camilleri","year":"2021","unstructured":"Camilleri M, Cuadrado M, Phillips E, Wilson W, Jenner R, Pang G, et al. Thrombotic microangiopathy in untreated myeloma patients receiving carfilzomib, cyclophosphamide and dexamethasone on the CARDAMON study. Br J Haematol. 2021;193:750\u201360.","journal-title":"Br J Haematol"},{"key":"3996_CR9","doi-asserted-by":"publisher","first-page":"e239091","DOI":"10.1136\/bcr-2020-239091","volume":"14","author":"A Darwin","year":"2021","unstructured":"Darwin A, Malpica L, Dhanoa J, Hashmi H. Carfilzomib-induced atypical haemolytic uraemic syndrome: a diagnostic challenge and therapeutic success. BMJ Case Rep. 2021;14:e239091.","journal-title":"BMJ Case Rep"},{"key":"3996_CR10","doi-asserted-by":"publisher","first-page":"539","DOI":"10.1016\/j.kint.2016.10.005","volume":"91","author":"TH Goodship","year":"2017","unstructured":"Goodship TH, Cook HT, Fakhouri F, Fervenza FC, Fr\u00e9meaux-Bacchi V, Kavanagh D, et al. Atypical hemolytic uremic syndrome and C3 glomerulopathy: conclusions from a \u201cKidney Disease: Improving Global Outcomes\u201d (KDIGO) Controversies Conference. Kidney Int. 2017;91:539\u201351.","journal-title":"Kidney Int"},{"key":"3996_CR11","doi-asserted-by":"publisher","first-page":"1129","DOI":"10.1056\/NEJMoa0707330","volume":"358","author":"V Eremina","year":"2008","unstructured":"Eremina V, Jefferson JA, Kowalewska J, Hochster H, Haas M, Weisstuch J, et al. VEGF inhibition and renal thrombotic microangiopathy. N Engl J Med. 2008;358:1129\u201336.","journal-title":"N Engl J Med"},{"key":"3996_CR12","doi-asserted-by":"publisher","first-page":"1946","DOI":"10.1200\/JCO.19.00231","volume":"37","author":"RF Cornell","year":"2019","unstructured":"Cornell RF, Ky B, Weiss BM, Dahm CN, Gupta DK, Du L, et al. Prospective study of cardiac events during proteasome inhibitor therapy for relapsed multiple myeloma. J Clin Oncol. 2019;37:1946\u201355.","journal-title":"J Clin Oncol"},{"key":"3996_CR13","first-page":"3950","volume":"130","author":"WC Song","year":"2020","unstructured":"Song WC, FitzGerald GA. COVID-19, microangiopathy, hemostatic activation, and complement. J Clin Investig. 2020;130:3950\u20133.","journal-title":"J Clin Investig"},{"issue":"1","key":"3996_CR14","doi-asserted-by":"publisher","first-page":"063","DOI":"10.53022\/oarjst.2023.9.1.0061","volume":"10","author":"M Alick","year":"2023","unstructured":"Alick M, Lydia K, Bornwell S. Frequency of thrombotic microangiopathy in COVID-19 patients and its correlation with disease severity at Ndola teaching hospital and levy Mwanawasa university teaching hospital in Zambia. Open Access Res J Sci Technol. 2023;10(1):063\u201374.","journal-title":"Open Access Res J Sci Technol"},{"issue":"7","key":"3996_CR15","doi-asserted-by":"publisher","first-page":"e28946","DOI":"10.1002\/jmv.28946","volume":"95","author":"Q Ma","year":"2023","unstructured":"Ma Q, Xu G. New-onset and relapsed thrombotic microangiopathy post-COVID-19 vaccination. J Med Virol. 2023;95(7):e28946.","journal-title":"J Med Virol"},{"issue":"2","key":"3996_CR16","doi-asserted-by":"publisher","first-page":"309","DOI":"10.1007\/s00277-020-04366-y","volume":"100","author":"MS Rahi","year":"2021","unstructured":"Rahi MS, Jindal V, Reyes SP, Gunasekaran K, Gupta R, Jaiyesimi I. Hematologic disorders associated with COVID-19: a review. Ann Hematol. 2021;100(2):309\u201320.","journal-title":"Ann Hematol"},{"key":"3996_CR17","doi-asserted-by":"publisher","DOI":"10.1042\/BSR20210611","author":"LM Grobbelaar","year":"2021","unstructured":"Grobbelaar LM, Venter C, Venter M, Ngoepe M, Laubscher GJ, Laubscher PJ, et al. SARS-CoV-2 spike protein S1 induces fibrin(ogen) resistant to fibrinolysis: implications for microclot formation in COVID-19. Biosci Rep. 2021. https:\/\/doi.org\/10.1042\/BSR20210611.","journal-title":"Biosci Rep"},{"key":"3996_CR18","doi-asserted-by":"publisher","DOI":"10.7759\/cureus.27962","author":"K Boldig","year":"2022","unstructured":"Boldig K, Batra R, Villegas A. COVID-19: a rare cause of hemolytic uremic syndrome. Cureus. 2022. https:\/\/doi.org\/10.7759\/cureus.27962.","journal-title":"Cureus"},{"issue":"16","key":"3996_CR19","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1186\/s12959-018-0168-2","volume":"11","author":"H Wada","year":"2018","unstructured":"Wada H, Matsumoto T, Suzuki K, Imai H, Katayama N, Iba T, et al. Differences and similarities between disseminated intravascular coagulation and thrombotic microangiopathy. Thromb J. 2018;11(16):14.","journal-title":"Thromb J"},{"key":"3996_CR20","doi-asserted-by":"publisher","first-page":"1207225","DOI":"10.3389\/fcimb.2023.1207225","volume":"13","author":"W Guo","year":"2023","unstructured":"Guo W, Zheng Y, Feng S. Omicron related COVID-19 prevention and treatment measures for patients with hematological malignancy and strategies for modifying hematologic treatment regimes. Front Cell Infect Microbiol. 2023;13:1207225.","journal-title":"Front Cell Infect Microbiol"},{"key":"3996_CR21","doi-asserted-by":"publisher","first-page":"412","DOI":"10.1016\/j.jinf.2023.01.024","volume":"86","author":"SW Kang","year":"2023","unstructured":"Kang SW, Kim JW, Kim JY, Lim SY, Jang CY, Chang E, et al. Characteristics and risk factors of prolonged viable virus shedding in immunocompromised patients with COVID-19: a prospective cohort study. J Infect. 2023;86:412\u20134.","journal-title":"J Infect"},{"key":"3996_CR22","doi-asserted-by":"publisher","first-page":"e0063222","DOI":"10.1128\/aac.00632-22","volume":"66","author":"R Shimizu","year":"2022","unstructured":"Shimizu R, Sonoyama T, Fukuhara T, Kuwata A, Matsuo Y, Kubota R. Safety, tolerability, and pharmacokinetics of the novel antiviral agent ensitrelvir fumaric acid, a SARS-CoV-2 3CL protease inhibitor, in healthy adults. Antimicrob Agents Chemother. 2022;66:e0063222.","journal-title":"Antimicrob Agents Chemother"},{"key":"3996_CR23","doi-asserted-by":"publisher","first-page":"1403","DOI":"10.1093\/cid\/ciac933","volume":"76","author":"H Mukae","year":"2023","unstructured":"Mukae H, Yotsuyanagi H, Ohmagari N, Doia Y, Sakaguchi H, Sonoyama T, et al. Efficacy and safety of ensitrelvir in patients with mild-to-moderate coronavirus disease 2019: the phase 2b part of a randomized, placebo-controlled, phase 2\/3 study. Clin Infect Dis. 2023;76:1403\u201311.","journal-title":"Clin Infect Dis"},{"issue":"9","key":"3996_CR24","doi-asserted-by":"publisher","first-page":"946","DOI":"10.1016\/j.jiac.2024.02.015","volume":"30","author":"M Yamato","year":"2023","unstructured":"Yamato M, Kinoshita M, Miyazawa S, Seki M, Mizuno T, Sonoyama T. Ensitrelvir in patients with SARS-CoV-2: a retrospective chart review. J Infect Chemother. 2023;30(9):946\u201350.","journal-title":"J Infect Chemother"},{"key":"3996_CR25","doi-asserted-by":"publisher","first-page":"1287300","DOI":"10.3389\/fimmu.2024.1287300","volume":"15","author":"C Furuya","year":"2024","unstructured":"Furuya C, Yasuda H, Hiki M, Shirane S, Yamana T, Uchimura A, et al. Case report: Ensitrelvir for treatment of persistent COVID-19 in lymphoma patients: a report of two cases. Front Immunol. 2024;15:1287300.","journal-title":"Front Immunol"},{"key":"3996_CR26","doi-asserted-by":"publisher","first-page":"2014","DOI":"10.1182\/bloodadvances.2021006333","volume":"6","author":"JSK Teh","year":"2022","unstructured":"Teh JSK, Coussement J, Neoh ZCF, Spelman T, Lazarakis S, Slavin MA, et al. Immunogenicity of COVID-19 vaccines in patients with hematologic malignancies: a systematic review and meta-analysis. Blood Adv. 2022;6:2014\u201334.","journal-title":"Blood Adv"}],"container-title":["International Journal of Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12185-025-03996-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12185-025-03996-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12185-025-03996-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,6]],"date-time":"2025-09-06T13:18:14Z","timestamp":1757164694000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12185-025-03996-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5,5]]},"references-count":26,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2025,9]]}},"alternative-id":["3996"],"URL":"https:\/\/doi.org\/10.1007\/s12185-025-03996-0","relation":{},"ISSN":["0925-5710","1865-3774"],"issn-type":[{"type":"print","value":"0925-5710"},{"type":"electronic","value":"1865-3774"}],"subject":[],"published":{"date-parts":[[2025,5,5]]},"assertion":[{"value":"14 September 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 April 2025","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 April 2025","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 May 2025","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"Informed consent was obtained from the participant.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"The participant has consented to the submission of the case report to the journal.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to publish"}},{"value":"Ethical approval was obtained by the Institutional committee of Eiju General Hospital.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}}]}}